Shipping
Same-day shipping on USA orders placed before 2PM EST.
View Shipping Policy →
99%+ Purity Guaranteed
Research Use Only
Secure Checkout
Ipamorelin 2mg
SKU: IPAMRLN2M
Same Trusted Formula. Fresh New Look.During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly the same as per our standards.
Accepted Payment MethodsYour data is protected with 256-bit encryption.
Returns
30-day hassle-free returns on unopened products.
View Returns Policy →Lab Tested
Every batch is tested for purity, potency and quality.
View Lab Results →Support
Have a question? Our team is here to help you.
Contact Us →Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction and ligand-receptor interactions. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signaling pathway characterization, structure-activity relationship investigations, and comparative analyses of growth hormone secretagogue receptor ligands.
- High Purity — 99%+ Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure of C38H49N9O5
CarbonHydrogenFluorineNitrogenOxygenSulfur
| Chemical Formula | C38H49N9O5 |
|---|---|
| Synonyms | 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, C38H49N9O5, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037 |
| Molar Mass | 711.9 g/mol |
| CAS Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Total Compound Content | 2 mg per vial |
| Shelf Life | 36 months |
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). Its defining pharmacological characteristic is a high degree of receptor selectivity relative to earlier growth hormone secretagogue receptor ligands, making it a valuable tool for investigating GHS-R1a-mediated signaling pathways and ligand-receptor interactions. Activation of GHS-R1a by Ipamorelin initiates Gq/11-coupled phospholipase C signaling, resulting in IP3 and DAG second-messenger generation, intracellular calcium mobilization, and downstream signal transduction events. Pharmacokinetic investigations have characterized the compound's receptor engagement profile and elimination dynamics in experimental systems. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signal transduction characterization, structure-activity relationship investigations, and comparative analyses of selective growth hormone secretagogue receptor ligands. Supplied as a lyophilized preparation (2 mg/vial). Independently third-party HPLC-tested; COA available per batch.
Ipamorelin (HPLC)
June 16, 2026 · Janoshik
What makes Ipamorelin more selective than other GHS-R1a agonists?
Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.
What is the pharmacokinetic profile of Ipamorelin?
Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.
How does Ipamorelin compare with GHRH analogues in receptor pharmacology research?
Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.
